FPRXinactive

FIVE PRIME THERAPEUTICS, INC.

Healthcare·Oncology·Phase 3
Oncology

FIVE PRIME THERAPEUTICS, INC. (FPRX): 5 pipeline candidates. Updated within the last hour.

9.0/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for FIVE PRIME THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$69.4M

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (5 candidates)

DrugPhase
bemarituzumabPhase 3
bms-986258Phase 1
fpa150Phase 1
fpa157Preclinical
fpt155Phase 1
·CEO: Oyster Point Boulevard

Frequently asked questions

How many drug candidates are in FIVE PRIME THERAPEUTICS, INC.'s pipeline?

FIVE PRIME THERAPEUTICS, INC. (FPRX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is FIVE PRIME THERAPEUTICS, INC.'s lead drug candidate?

FIVE PRIME THERAPEUTICS, INC.'s most advanced tracked candidate is bemarituzumab (Phase 3) for Gastric or gastroesophageal junction (GEJ) cancer.

Who is the CEO of FIVE PRIME THERAPEUTICS, INC.?

Oyster Point Boulevard is the chief executive officer of FIVE PRIME THERAPEUTICS, INC. (FPRX).

Get the full picture on FIVE PRIME THERAPEUTICS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar